Latest Prescription Drugs news

Effects on Quality of Life Mixed for Tx of Multiple Myeloma

Most dimensions of quality of life (QoL) are impaired in patients with relapsed/refractory multiple myeloma, and treatment may have mixed effects on QoL, according to a study published online Sept. 26 in Leukemia & Lymphoma.

Triplet Tx Ups Survival in BRAF V600E-Mutated Colorectal Cancer

A triplet combination of therapies (encorafenib, cetuximab, and binimetinib) results in significantly longer overall survival and a higher response rate than standard therapy in patients with metastatic colorectal cancer with the BRAF V600E mutation, according to a study published online Sept. 30 in the New England Journal of Medicine. The research was published to coincide with the European Society of Medical Oncology Congress 2019, held from Sept. 27 to Oct. 1 in Barcelona, Spain.

Nintedanib Slows Fibrosing Interstitial Lung Disease

For patients with progressive fibrosing interstitial lung diseases, nintedanib is associated with a lower rate of decline in forced vital capacity compared with placebo, according to a study published online Sept. 29 in the New England Journal of Medicine to coincide with the European Respiratory Society International Congress 2019, held from Sept. 28 to Oct. 2 in Madrid.

Less Bleeding With Ticagrelor Alone in High-Risk Patients

Ticagrelor alone results in less bleeding than ticagrelor plus aspirin among high-risk patients who have undergone percutaneous coronary intervention and received dual antiplatelet therapy for three months, according to a study published online Sept. 26 in the New England Journal of Medicine. The research was published to coincide with Transcatheter Cardiovascular Therapeutics 2019, the annual meeting of the Cardiovascular Research Foundation, held from Sept. 25 to 29 in San Francisco.